Detalus Advisors’s Gilead Sciences GILD Stock Holding History

Detalus Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-7,350	Closed	-$453K	–	140
2022 Q3	$453K	Sell	7,350 -225	-3%	-$14.2K	0.27%	73
2022 Q2	$468K	Buy	7,575 +100	+1%	+$6.19K	0.28%	66
2022 Q1	$444K	Buy	7,475 +1,175	+19%	+$75.1K	0.23%	71
2021 Q4	$457K	Buy	6,300 +900	+17%	+$62K	0.22%	69
2021 Q3	$377K	Buy	5,400 +100	+2%	+$7.03K	0.19%	79
2021 Q2	$365K	Buy	5,300 +1,600	+43%	+$107K	0.19%	82
2021 Q1	$239K	Buy	3,700 +200	+6%	+$12.9K	0.14%	94
2020 Q4	$204K	Buy	+3,500	New	+$211K	0.13%	93

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Detalus Advisors's GILD Position: Q4 2022 in Review

Detalus Advisors sold out of Gilead Sciences (GILD) in Q4 2022, closing a stake of 7,350 shares — an estimated $453K sold.

Detalus Advisors first reported a position in GILD in Q4 2020 and held it in 8 quarters. The position peaked at $468K in Q2 2022. 1,767 funds tracked by Wall St. Rank hold GILD as of Q4 2022.

Detalus Advisors reported no remaining Gilead Sciences position as of Q4 2022 after selling out during the quarter.
Detalus Advisors sold 7,350 Gilead Sciences shares in Q4 2022, an estimated $453K.
Detalus Advisors first reported a position in Gilead Sciences in Q4 2020 and held it in 8 quarters.
Detalus Advisors's Gilead Sciences position peaked at $468K in Q2 2022.
1,767 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2022.

Based on Detalus Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.